Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.40 |
| ▸ | ERCC1 | P07992 | 2/20 | 0.40 |
| ▸ | FEN1 | P39748 | 2/20 | 0.40 |
| ▸ | ERCC4 | Q92889 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | ALPI | P09923 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | GRK6 | P43250 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HPGDS | O60760 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28061565 | 1.00 | SLC7A5 (0.43) | SLC7A5CYP3A4PDE10ANTRK1ERCC1 | |
| SCHEMBL28061540 | 0.88 | PDE10A (0.41) | PDE10ANTRK1ERCC1FEN1ERCC4 | |
| SCHEMBL25754931 | 0.72 | PIN1 (0.58) | CYP3A4ERCC1FEN1ERCC4PKM | |
| SCHEMBL13095827 | 0.71 | SLC7A5 (0.54) | SLC7A5CYP3A4PKMALPIPTGS1 | |
| SCHEMBL59810 | 0.71 | SLC7A5 (0.54) | SLC7A5CYP3A4PKMALPIPTGS1 | |
| SCHEMBL5289317 | 0.71 | SLC7A5 (0.54) | SLC7A5CYP3A4PKMALPIPTGS1 | |
| SCHEMBL4854900 | 0.71 | SLC7A5 (0.54) | SLC7A5CYP3A4PKMALPIPTGS1 | |
| SCHEMBL59078 | 0.71 | SLC7A5 (0.54) | SLC7A5CYP3A4PKMALPIPTGS1 | |
| SCHEMBL22403244 | 0.71 | SLC7A5 (0.50) | SLC7A5CYP3A4PKMALPIPTGS1 | |
| SCHEMBL8957140 | 0.70 | SLC7A5 (0.54) | SLC7A5CYP3A4PKMALPIPTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 402 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109988312-A | A kind of poly amic acid ester, preparation method and negative polyimide composition and application | 深圳先进技术研究院 | 2019-07-09 | — | — | CN | claimed |
| CN-109946925-A | A kind of compound is promoting the application in polyimides low-temperature setting, polyimide precursor composition and application thereof | 深圳先进技术研究院 | 2019-06-28 | — | — | CN | claimed |
| CN-102596915-B | The synthetic method of 2-thiolhistidine and analogue | TETRAHEDRON (FR) | 2016-04-20 | — | — | CN | claimed |
| US-20090281093-A1 | ANTI-INFLAMMATORY COMPOUNDS | C.T.G. PHARMA S.R.L. (IT) | 2009-11-12 | — | — | US | claimed |
| US-20090275539-A1 | Nuclear Transcription Factors Regulators | CTG PHARMA S.R.L. (IT) | 2009-11-05 | — | — | US | claimed |
| US-20090227597-A1 | PYRAZOLOPYRIMIDINONES AS PHOSPHODIESTERASE INHIBITORS | CTG PHARMA S.R.L. (IT) | 2009-09-10 | — | — | US | claimed |
| US-20080207751-A1 | Sulindac Derivatives for Treatment of Cancer | SULFIDRIS S.R.L. (IT) | 2008-08-28 | — | — | US | claimed |
| EP-1904440-A1 | SULINDAC DERIVATIVES FOR TREATMENT OF CANCER | Sulfidris S.r.l. (IT) | 2008-04-02 | — | — | EP | claimed |
| EP-1871360-A1 | NEW ANTI-INFLAMMATORY COMPOUNDS | CTG Pharma S.r.l. (IT) | 2008-01-02 | — | — | EP | claimed |
| WO-2006134489-A1 | SULINDAC DERIVATIVES FOR TREATMENT OF CANCER | SULFIDRIS S.R.L. (IT) | 2006-12-21 | — | — | WO | claimed |
| WO-2006111791-A1 | NEW ANTI-INFLAMMATORY COMPOUNDS | CTG PHARMA S.R.L. (IT) | 2006-10-26 | — | — | WO | claimed |
| WO-2006037623-A2 | NEW NUCLEAR TRANSCRIPTION FACTORS REGULATORS | CTG PHARMA S.R.L. (IT) | 2006-04-13 | — | — | WO | claimed |
| EP-1645288-A1 | New nuclear transcription factors regulators | CTG Pharma S.r.l. (IT) | 2006-04-12 | — | — | EP | claimed |
| EP-1630164-A1 | Pyrazolopyrimidinones as phosphodiesterase inhibitors | Expotrend Company SA (CH) | 2006-03-01 | — | — | EP | claimed |
| WO-1995029930-A2 | IMPROVED METHOD FOR OLIGONUCLEOTIDE ANALOG SYNTHESIS | GILEAD SCIENCES, INC. (US) | 1995-11-09 | — | — | WO | claimed |
| JP-58216192-A | — | — | None | — | — | JP | disclosed |
| JP-58219186-A | — | — | None | — | — | JP | disclosed |
| JP-S58216192-A | NOVEL PENICILLIN COMPOUND | ASAHI CHEM IND CO LTD | 1983-12-15 | — | — | JP | disclosed |
| EP-0068403-A2 | Cephalosporin compound | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1983-01-05 | — | — | EP | disclosed |
| JP-S57212189-A | NOVEL CEPHALOSPORIN COMPOUND | ASAHI CHEM IND CO LTD | 1982-12-27 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207751-A1 | Sulindac Derivatives for Treatment of Cancer | PTGES3, PTGES2, PTGS1 | SLC7A5 2938/4885CYP3A4 395/4885PDE10A 2528/4885 |
| US-20090227597-A1 | PYRAZOLOPYRIMIDINONES AS PHOSPHODIESTERASE INHIBITORS | PDE3A, PDE3B, PDE2A | SLC7A5 2628/4885CYP3A4 1082/4885PDE10A 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.